Antidiabetic Biosimilars Market by Product,
End-user and Geography - Trends and
Analysis till 2024
Antidiabetic biosimilars market overview
Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics
include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas,
insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product
that is approved on the basis that it is highly similar to a FDA approved biological product known as
a reference product. Biosimilar manufacturers need to generate data from lab testing and clinical
testing to demonstrate that the biosimilar developed provides the same therapeutic benefit to
patients as the reference product.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/92
Patent expiries to drive growth of the global antidiabetic biosimilars market
The global antidiabetic biosimilars market is driven by increasing number of diabetes mellitus
patients. According to World Health Organization (WHO) the number of people suffering from
diabetes stood at 422 million in 2014. The global prevalence of diabetes among adults above 18
years increased to 8.5% in 2014 from 4.7% in 1980. Increasing incidence of lifestyle disorders such
as obesity, increases the risk of diabetes and in turn drives growth of the antidiabetic biosimilars
market. In June 2014, the European Medicines Agency authorized the first biosimilar of insulin
Glargine, Abasaglar from Eli Lilly and Company and Boehringer Ingelhim International Gmbh, for
treatment of diabetes mellitus. The biosimilar received U.S. FDA approval in 2016, which would
fuel growth of the antidiabetic biosimilars market.